Orchid Pharma Limited (ORCHPHARMA) — Corporate Action
Orchid Pharma announced NCLT approval of its amalgamation with Dhanuka Laboratories, effective April 1, 2024, creating a combined entity with Rs.1400-1500 crore turnover and Rs.200-250 crore EBITDA. The scheme consolidates operations, eliminates inter-company transactions, and requires statutory filings. Shareholders retain voting rights while creditors approved the restructuring unanimously. The order permits interested parties to seek further directions before finalization.
About Orchid Pharma Limited (ORCHPHARMA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when ORCHPHARMA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ORCHPHARMA — Free💡 Ask AI about this filing
📊 More ORCHPHARMA filings
- share transfer — 11 July 2026 Orchid Pharma confirmed compliance with SEBI Depositories and Participants Regulations 2018 for Q1 F...
- Financial Results — 26 June 2026 Orchid Pharma announced that its trading window will close on July 1, 2026, ahead of the unaudited l...
- Announcement — 11 June 2026 Orchid Pharma disclosed a GST department order demanding Rs. 1.67 crores plus interest for a pre-acq...
- 🔴 Corporate Action — 5 June 2026 Orchid Pharma announced that the National Company Law Tribunal approved the merger of Dhanuka Labora...
- 🔴 Financial Results — 1 June 2026 Orchid Pharma reported Q4 FY26 revenue of **₹238 crores** and FY26 revenue of **₹811 crores**, with ...
🔥 Also filed on 12 June 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when ORCHPHARMA files new disclosures
Track ORCHPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ORCHPHARMA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research